Disorder Related to Bone Marrow Transplantation
6
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
33%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
Long Term Minor Sibling Donor Well-Being